Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNA, U6 small nuclear 402, pseudogene (RNU6-402P) is a processed pseudogene of the U6 small nuclear RNA (snRNA) family found in the human genome[2][3]. U6 snRNA is a noncoding, uridine-rich RNA essential for nuclear intron splicing as part of the spliceosome complex[1]. However, RNU6-402P does not produce a functional RNA or protein; it is a "pseudogene," meaning it is a DNA sequence derived from the parental U6 snRNA gene but has lost its original function due to mutation or loss of regulatory elements[2][3]. Pseudogenes like RNU6-402P are created largely by retrotransposition—a mechanism in which the RNA of parent genes is reverse-transcribed and inserted back into the genome—often with the involvement of LINE-1 (L1) elements[1][3]. RNU6-402P and other snRNA pseudogenes serve as evolutionary markers of retrotransposition dynamics and genome organization but are not considered therapeutic drug targets, nor are they involved in recognized biological or disease processes[3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 402, pseudogene (RNU6-402P).